search

Active clinical trials for "Colonic Neoplasms"

Results 331-340 of 1014

A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU,...

Mucinous Adenocarcinoma of the ColonMucinous Adenocarcinoma of the Rectum14 more

Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of colorectal cancer by blocking blood flow to the tumor. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining erlotinib and bevacizumab with combination chemotherapy may kill more tumor cells. This phase I trial is studying the side effects and best dose of erlotinib when given together with bevacizumab, fluorouracil, leucovorin, and oxaliplatin in treating patients with metastatic or locally advanced colorectal cancer.

Completed40 enrollment criteria

Study Evaluating EKB-569 in Advanced Colorectal Cancer

Colorectal NeoplasmsColonic Neoplasms1 more

This non-randomized, open-label, outpatient clinical trial is designed to assess the safety and efficacy of daily orally administered EKB-569 in subjects with advanced colorectal cancer. Patients must have been previously treated with a fluoropyrimidine (5-FU or capecitabine) and either oxaliplatin or irinotecan (given concurrently or as separate regimens). The primary objective of the study is to assess the clinical activity of EKB-569 administered orally as a second-line or later stage treatment in subjects with advanced colorectal cancer. Secondary objectives include: To further evaluate the safety of EKB-569 To explore additional clinical activity parameters To explore subject survival To evaluate the pharmacokinetics of EKB-569 To assess subject reported outcomes EKB-569 will be administered orally as a single-agent. Eligible subjects will take EKB-569 daily as long as they do not have progressive disease and are tolerating treatment.

Completed6 enrollment criteria

Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer

Recurrent Colon CancerRecurrent Rectal Cancer2 more

Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have stage IV colorectal cancer. Imatinib mesylate may interfere with the growth of tumor cells by blocking certain enzymes necessary for cancer cell growth

Completed30 enrollment criteria

Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer

Colorectal CancerColon Cancer5 more

The purpose of this trial is to determine the safety of hMN14 at different dose levels in the treatment of either colorectal or breast cancer.

Completed14 enrollment criteria

Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic...

Adenocarcinoma of the ColonAdenocarcinoma of the Rectum5 more

Phase II trial to study the effectiveness of hepatic arterial infusion plus chemotherapy in treating patients who have colorectal cancer metastatic to the liver. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different combinations and different ways may kill more tumor cells.

Completed36 enrollment criteria

Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating...

Adenocarcinoma of the ColonAdenocarcinoma of the Rectum6 more

Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without bevacizumab in treating patients who have advanced or metastatic colorectal cancer that has been previously treated. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as bevacizumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining monoclonal antibody therapy with combination chemotherapy may kill more tumor cells. It is not yet known if bevacizumab is more effective with or without combination chemotherapy in treating colorectal cancer

Completed37 enrollment criteria

Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer

Recurrent Colon CancerExtensive Stage Small Cell Lung Cancer12 more

RATIONALE: Vaccines made from mutated ras peptides may make the body build an immune response to and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer.

Completed13 enrollment criteria

GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic...

Recurrent Colon CancerRecurrent Rectal Cancer8 more

This phase I trial is studying the side effects and best dose of capecitabine when given together with GTI-2040 and oxaliplatin in treating patients with locally advanced or metastatic colorectal cancer or other solid tumors. Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. GTI-2040 may increase the effectiveness of chemotherapy by making tumor cells more sensitive to the drugs. Giving GTI-2040 together with oxaliplatin and capecitabine may kill more tumor cells

Completed23 enrollment criteria

Clinical Trial in Patients With Metastatic Colorectal Cancer

Colon CancerRectal Cancer

The objectives of this trial are to determine if CoFactor in combination with 5-FU are effective in the treatment of metastatic colorectal cancer and to determine the side effects observed with the administration of CoFactor and 5-FU.

Completed17 enrollment criteria

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu...

Advanced Adult Primary Liver CancerAnaplastic Thyroid Cancer125 more

Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Phase I trial to study the effectiveness of interleukin-12 and trastuzumab in treating patients who have cancer that has high levels of HER2/neu and has not responded to previous therapy

Completed26 enrollment criteria
1...333435...102

Need Help? Contact our team!


We'll reach out to this number within 24 hrs